On Target Podcast

Connie Lehman, founder and CEO of Clairity, shares how AI-driven insights can improve early detection, personalize screening, and ultimately change the future of breast-cancer care.

Dawn Mattoon, CEO of Mercy Bioanalytics, explains how her company is using extracellular vesicles to successfully diagnose early stage cancer.

Doug Biehn, President and CEO of Octave Biosciences, talks about the difference that a biomarker test can make in the management of multiple sclerosis.

Alec Ford, CEO of Karius, shares how genomics and AI are expanding what's possible in infectious disease diagnostics — and why getting the right answer faster can make all the difference for immunocompromised patients battling cancer and other serious conditions.

Irene Ghobrial, founder of Predicta Biosciences, explains how bringing whole-genome sequencing into the clinic is taking diagnosis and treatment of multiple myeloma and blood cancers to a new level of precision.

Alka Chaubey, CMO of Bionano Genomics, explains how optical genome mapping addresses the unmet needs of cytogenomics - and what it takes to get pathbreaking new technology into the clinic.

Susan Tousi, CEO of DELFI Diagnostics, shares how her company is using AI and fragmentomics to make liquid biopsy more accessible and cancer less deadly.

James Lu, co-founder and CEO of Helix, tells us what his company is doing to make genomics part of the standard portfolio of health-care data.

Julia Cheek, founder and CEO of Everlywell, shares how her company is working to change not only the way people access, use, and understand home tests, but the way home tests fit into the entire landscape of medicine.

Katherine Stueland, CEO of GeneDx, shares how her company is scaling whole-genome and exome sequencing for the diagnosis of rare diseases.